Growth Metrics

AbCellera Biologics (ABCL) Retained Earnings (2020 - 2025)

AbCellera Biologics' Retained Earnings history spans 6 years, with the latest figure at -$2.7 million for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 118.99% year-over-year to -$2.7 million, compared with a TTM value of -$2.7 million through Sep 2025, down 118.99%, and an annual FY2024 reading of -$4.4 million, down 154.53% over the prior year.
  • Retained Earnings for Q3 2025 was -$2.7 million at AbCellera Biologics, down from $36.6 million in the prior quarter.
  • The five-year high for Retained Earnings was $456.1 million in Q3 2022, with the low at -$4.4 million in Q4 2024.
  • Average Retained Earnings over 5 years is $117.5 million, with a median of $787000.0 recorded in 2022.
  • Year-over-year, Retained Earnings surged 152108.93% in 2022 and then tumbled 429.69% in 2023.
  • Tracing ABCL's Retained Earnings over 5 years: stood at $280000.0 in 2021, then surged by 152108.93% to $426.2 million in 2022, then crashed by 100.4% to -$1.7 million in 2023, then plummeted by 154.53% to -$4.4 million in 2024, then skyrocketed by 38.37% to -$2.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Retained Earnings are -$2.7 million (Q3 2025), $36.6 million (Q2 2025), and $71.3 million (Q1 2025).